Spherix Global Insights

August 10, 2017

RealTime Dynamix™: Inflammatory Bowel Disorder US Q3

Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), and Crohn’s Disease (CD) currently affects the lives of approximately 1.6 million Americans. The use of biologics has changed the face of treatment for moderate-to-severe IBD patients. However, recent launches, an active pipeline, and the introduction of biosimilars present an opportunity for major future shifts in the IBD landscape.

RealTime Dynamix™: IBD (US) report series provides a detailed and timely look at current and future trends in the IBD market, and the effects of the future shifting landscape. The quarterly releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated quarterly. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the IBD market make this an essential tool for companies competing in the space, as well as those with near term plans to enter it.

Download Report Overview

About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact:
Telephone: (800) 661-0571
Email: info@spherixglobalinsights.com